Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Elymus repens pollen is a non-standardized allergenic extract derived from the pollen of Elymus repens, commonly known as couch grass or quack grass. Developed and manufactured by ALK-Abello, it is a biologic product used for both the diagnosis and treatment of allergies specific to this pollen. For diagnosis, it is administered via percutaneous (prick) or intradermal skin tests to identify sensitization. As a therapeutic agent, it is used in allergen-specific immunotherapy, typically administered through subcutaneous injections. The treatment works by gradually exposing the patient's immune system to the allergen, which induces immune tolerance, reduces the production of IgE antibodies, and promotes a shift towards a non-allergic immune response, thereby mitigating symptoms of allergic rhinitis and conjunctivitis upon natural exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on elymus repens pollen.